On Monday, Shares of Encana Corp (USA) (NYSE:ECA), added 1.91% and closed at $10.67 in the last trading session. The last trading range of the stock ranges between $10.42 and $10.77. Encana Corporation, together with its auxiliaries, engages in the development, exploration, production, and marketing of natural gas, oil, and natural gas liquids in Canada and the United States. The company owns interests in plays, such as the Montney in northern British Columbia and northwest Alberta; Duvernay in west central Alberta; and other upstream operations, counting Wheatland in southern Alberta, Deep Panuke located offshore Nova Scotia, and Horn River in northeast British Columbia. It also holds interests in plays that comprise the Eagle Ford in south Texas; Permian in west Texas; DJ Basin in northern Colorado; San Juan in northwest New Mexico; Piceance in northwest Colorado; and Tuscaloosa Marine Shale in east Louisiana and west Mississippi.
Yum! Brands, Inc. (NYSE:YUM), jumped 0.12% and closed at $90.92 in the last trading session. The last trading range of the stock ranges between $90.52 and $91.28. The company’s Market capitalization is $35.84 Billion with the total Outstanding Shares of 389.89 million. To kick off the 32nd year of the BOOK IT! Program, Pizza Hut® unveiled its first-ever Page Turner Grant program to support individuals and organizations in local communities that share the restaurant’s commitment to literacy and reading.
The BOOK IT! Program and Page Turner Grants are part of Pizza Hut: The Literacy Project, a broader commitment to literacy and reading declared earlier this fall. The aim of The Literacy Project is to impact 100 million people by enabling access to books and educational resources, empowering teachers and inspiring a lifelong love of reading.
“It’s vitally important for Pizza Hut to continue to make an impact in the local communities that we serve,” said Doug Terfehr, Senior Director, Social Impact at Pizza Hut. “The Page Turner Grant program is an opportunity to celebrate and support those who are taking the time to assist people become their best through literacy and reading. Whether fostering book ownership, providing resources for teachers or assisting students find the joy in reading, we are thrilled to provide this opportunity in our ongoing commitment to literacy.”
Aratana Therapeutics Inc (NASDAQ:PETX), gained 11.00% and closed at $10.39 in the last trading session. The last trading range of the stock ranges between $9.31 and $10.73. During the 52-week trading session the minimum price at which share price traded, registered at $2.56 and reached to max level of $10.73. Aratana Therapeutics, Inc. (PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, declared Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics will take part in a panel negotiation at the Jefferies Animal Health Leadership Summit recently in London titled “Competing with Giants: Strategies to Succeed in a Merged Market.” The event is open to the public, but will not be webcast.
At the event, Dr. St. Peter intends to discuss the commercial introduction of Aratana’s recently approved therapeutics and provide other business updates, counting:
- Aratana has recently hired about two dozen Therapeutic Specialists in territories across the United States and it intends to host its first National Sales Meeting the week of September 26, 2016 in Kansas City. The newly-hired sales representatives were selected from a pool of more than 3,000 candidates and are industry veterans, with an average of more than a decade of animal health experience. Regional Sales Leaders and Medical Scientific Liaisons, in addition to practiced sales and marketing leadership, round out the commercial organization.
- October 6-9, 2016, Aratana will attend the American College of Veterinary Surgeons (ACVS) Surgery Summit in Seattle, by which time Aratana believes its commercial organization will be fully operational. Aratana’s commercial focus during the fourth quarter of 2016 will be NOCITA® (bupivacaine liposome injectable suspension), a local post-operative analgesia for cranial cruciate ligament surgery in dogs.
- The Company will host an Aratana Counsel of Experts meeting September 22-23, 2016 and provide updates on its pipeline. With respect to its investigational therapeutic for canine osteosarcoma (AT-014), which is regulated by the U.S. Department of Agriculture (USDA), Aratana reports that enrollment in a safety study continues and Aratana anticipates USDA conditional licensure in the first half of 2017. With respect to its investigational allogeneic stem cell therapeutic for canine osteoarthritis pain (AT-016) that is regulated by the FDA’s Center for Veterinary Medicine (CVM), Aratana reports that results of a formerly revealed pilot field efficacy study have been published in the September 16, 2016 edition of Frontiers in Veterinary Science (“A Prospective, Randomized, Masked, and Placebo-Controlled Efficacy Study of Intraarticular Allogeneic Adipose Stem Cells for the Treatment of Osteoarthritis in Dogs”).